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The cell-free fetal DNA (cffDNA) is composed of small fragments of extracellular DNA
derived from the shedding of placental trophoblasts that goes under apoptosis. This cffDNA
fragments have a very short half-life and just represents the 10% of the cell-free DNA
detected on maternal plasma. Despite of this small fraction, the whole fetal genome is
represented in the cffDNA that can be found in the maternal bloodstream.
Since this discovery, many applications for cffDNA in non-invasive prenatal testing (NIPT)
have been developed [Figure 1].
Why monogenic diseases?
The application for NIPT in monogenic diseases had been a long time challenge, especially
for autosomal recessive disorders. The difficulty is caused by the coexistence of fetal and
maternal DNA in maternal plasma, this makes difficult to distinguish the maternally
inherited fetal allele from the background maternal DNA.
Figure 1. An overview of current non-invasive prenatal testing (NIPT) applications. Cell-free fetal DNA (cffDNA) proceed from
apoptotic trophoblast and cross the placenta for arrive to the mother’s blood stream. This cffDNA can be collected with a blood
sample and after its extraction, cffDNA can be used for NIPT. Many NIPT applications for cffDNA have been developed through
the years: establishing fetal sex or the Rhesus blood group type, screening for fetal aneuploidies, screening for microdeletions
and microduplications syndromes, diagnosis of monogenic disorders and also the fetal methylome and transcriptome have been
investigated.
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Despite the RHDO strategy works pretty well, the new strategies are focusing on guarantee
higher resolution and a precise quantification of mutant fetal alleles circulating. This could
be achieved by using the new single-molecule amplification and sequencing methodologies
[Figure 4]. But despite all the research and the improvements in the field there are still today
some challenges to overcome [Table 1].
Figure 4. Schematic timeline that represents the advances in NIPT field since the discovery of cffDNA in 1997. The challenge
is currently to tune up the protocols for NIPT employing the new single-molecule amplification and sequencing methodologies
like cSMART (circulating single-molecule amplification and resequencing technology); picodroplet digital PCR; Taqman probes
or MEMO (3’-Modified Oligonucleotide PCR). dPCR (digital PCR); RMD (relative mutation dosage) test.
CONCLUSIONS
First of all, the NIPT of recessive monogenic diseases constitutes just a complementary screening for invasive prenatal testing in clinical practice because of
the still presents challenges. However, even if the definitive clinical application of the NIPT, at least as screening, is no longer a distant future, if at the end
NIPT for autosomal recessive disorders and monogenic diseases in general could not be applied into clinical practice as an alternative for invasive prenatal
testing it will not be because the technical challenges cannot be overcome. In our opinion, the cause will be all the social and ethical considerations which
are equal, or even more important, than the reliability of the technique for the patients.
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NIPT for single gene disorders
Relative Haplotype Dosage (RHDO) Analysis
The NIPT for single gene disorders combine the power of the targeted massive parallel
sequencing (MPS) with a relative haplotype dosage (RHDO) test since it allows
establishing both parental inheritances.
Taking an hypothetical typical autosomal recessive
case where both parents are heterozygous carriers
and the couple is expecting a second child, the
RHDO process is carried out for a series of SNPs
within the same genomic region in order to
establish the inheritance from the fetus [Figure 2].
If the mother is a heterozygous carrier, the
combinations of SNPs would therefore form 2
different haplotypes. One haplotype is named
haplotype I and the other haplotype II respectively
(HapI or HaplI) [Figure 3]. In order to be
informative, those SNPs positions need to be
homozygous in the father. Those SNPs are classified
into type α or type β. A type α SNP is one which the
allele on the maternal haplotype is identical to the
paternal allele at the same SNP position. In
contrast, a type β SNP is the one which the allele on
the maternal haplotype is different from the
paternal one.
Figure 2. Schematic representation of a typical
pedigree from an autosomal recessive case.
After that the RHDO test is performed and depending on which type of SNPs are
overrepresented in the maternal plasma DNA it is possible to known which maternal
haplotype has been inherited by the fetus [Figure 3]. Also, knowing which is the maternal
mutant haplotype thanks to the proband, it is possible to establish if the fetus has inherited
or not the causative mutation from the mother. The same process is applied for detect the
paternal inheritance but in this case there is no need to perform a RHDO test because the
detection of a paternal haplotype absent in the mother but present at the maternal plasma
DNA will inform which paternal allele has been inherited by the fetus.
This is the common approach for NIPT and it could be applied to
any type of monogenic diseases. A good example of the use that
could have the clinical application of NIPT can be seen in the
congenital adrenal hyperplasia (CAH). CAH is a recessive autosomal
disease in which the excess of fetal androgen production causes
genital virilization in female fetuses. The genital organogenesis
begins at approximately 9 weeks of gestation but the invasive
prenatal testing is performed as soon at 14 weeks of gestation
making the preventive treatment with dexamethasone impossible.
So if NIPT could be applied on this type of cases, the status of the
fetus as affected or not could be established on time and the
treatment could be applied avoiding the disease effects.
Figure 3. Relative Haplotype Dosage (RHDO) test for an autosomal recessive disease case where both parents are
heterozygous. Pa (paternal haplotypes) and Ma (maternal haplotypes).
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